With a market cap of $50.5 billion, Edwards Lifesciences Corporation (EW) is a leading medical technology company specializing in structural heart disease treatments, particularly heart valve replacement and repair technologies. Headquartered in Irvine, California, the company pioneered the development of transcatheter aortic valve replacement (TAVR), a minimally invasive procedure that allows physicians to replace diseased heart valves without open-heart surgery.
Companies worth $10 billion or more are generally referred to as “large-cap stocks.” EW fits right into that category, with its market cap exceeding the threshold, reflecting its substantial size, influence, and dominance in the healthcare sector.
